NK Cell-Based Cancer Therapeutics

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing targeted natural killer (NK) cell therapies which are supported by Companion Diagnostics. Alphageneron’s team is comprised of industry veterans with experience in both large pharma and biotechnology startups who are committed to transforming the lives of patients with cancer. The Company is based in Boston, Massachusetts with European capabilities in Munich, Germany.

ENKASTIM™ is a targeted autologous NK cell therapy that activates the patient’s own NK cells to target cancers expressing membrane Hsp70 (“mHsp70”), a cancer-specific biomarker which is highly expressed on aggressive cancer cells, but not on non-cancerous cells. More …..

AP-161™ is an allogeneic targeted NK cell therapy that targets tumors expressing mHsp70. More …..

AP-205™ is being developed as an ‘off-the-shelf’ allogeneic CAR-engineered NK cell therapy which targets tumors expressing membrane Hsp70. More …..

AP-401™ is a novel Induced Pluripotent Stem Cell (iPSC) Bi-Specific CAR NK cell therapy targeting CD155 and CD73 which has shown promising efficacy to solid tumors in animal studies. More …..